{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T12:41:21Z","timestamp":1793104881819,"version":"4.5.0"},"reference-count":34,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","license":[{"start":{"date-parts":[[2018,5,1]],"date-time":"2018-05-01T00:00:00Z","timestamp":1525132800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["PR9"],"published-print":{"date-parts":[[2018,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction and objectives:<\/jats:title>\n                    <jats:p>Understanding the details of one individual's experience with pain, opioid use and withdrawal may generate insights into possible relationships between opioid-induced hyperalgesia and withdrawal-associated injury site pain (WISP).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>This case study was extracted from a mixed methods study that characterized WISP. In 2014, the individual was recruited from a primary care clinic that prescribes opioid agonist therapy. In an interview, she completed a 35-item survey and elaborated on her own experience. Follow-up contact was made in June of 2017.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>This 34-year-old white woman had several twisting injuries of her right knee between ages 13 and 15. The pain resolved each time in a few days, and she was pain free for 15 years. Around age 30, she initiated illicit oxycodone recreationally (not for pain) and developed an opioid use disorder. On detoxification, she experienced severe knee pain for 6 weeks that resolved postdetoxification but returned after subsequent oxycodone use and withdrawal episodes along with generalized skin sensitivity. This experience of WISP became a barrier to opioid cessation. Although nonsteroidal anti-inflammatories and gabapentin relieved WISP and methadone therapy assisted her opioid use disorder, an eventual change to sublingual buprenorphine\/naloxone provided superior control of both.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>This case report illustrates that both opioid use and withdrawal can reactivate injury site pain, which can increase with dose escalation and repeated withdrawal events. The timing, trajectory, and neuropathic features of WISP reported here are consistent with those previously reported for the development of opioid-induced hyperalgesia, possibly linking these phenomena.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/pr9.0000000000000648","type":"journal-article","created":{"date-parts":[[2018,4,6]],"date-time":"2018-04-06T18:14:46Z","timestamp":1523038486000},"page":"e648","source":"Crossref","is-referenced-by-count":11,"title":["Linking opioid-induced hyperalgesia and withdrawal-associated injury site pain: a case report"],"prefix":"10.1097","volume":"3","author":[{"given":"Launette Marie","family":"Rieb","sequence":"first","affiliation":[{"name":"Department of Family Practice, University of British Columbia, Vancouver, BC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy V.","family":"Norman","sequence":"additional","affiliation":[{"name":"Department of Family Practice, University of British Columbia, Vancouver, BC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth Elwood","family":"Martin","sequence":"additional","affiliation":[{"name":"Department of Family Practice, University of British Columbia, Vancouver, BC, Canada"},{"name":"School of Population and Public Health, University of British Columbia, Vancouver, BC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Berkowitz","sequence":"additional","affiliation":[{"name":"Sauder School of Business, University of British Columbia, Vancouver, BC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evan","family":"Wood","sequence":"additional","affiliation":[{"name":"BC Centre on Substance Use, St. Paul's Hospital, Vancouver, BC, Canada"},{"name":"Department of Medicine, University of British Columbia, Vancouver, BC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael John","family":"Milloy","sequence":"additional","affiliation":[{"name":"BC Centre on Substance Use, St. Paul's Hospital, Vancouver, BC, Canada"},{"name":"Department of Medicine, University of British Columbia, Vancouver, BC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan","family":"McNeil","sequence":"additional","affiliation":[{"name":"BC Centre on Substance Use, St. Paul's Hospital, Vancouver, BC, Canada"},{"name":"Department of Medicine, University of British Columbia, Vancouver, BC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2018,5]]},"reference":[{"key":"R1-20230824","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1007\/s40263-015-0255-x","article-title":"Targeting opioid-induced hyperalgesia in clinical treatment: neurobiological considerations","volume":"29","author":"Arout","year":"2015","journal-title":"CNS Drugs"},{"key":"R2-20230824","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.pmr.2014.12.001","article-title":"Opioid therapy in chronic pain","volume":"26","author":"Ballantyne","year":"2015","journal-title":"Phys Med Rehabil Clin N Am"},{"key":"R3-20230824","first-page":"116","article-title":"Opioid-induced hyperalgesia: where are we now?","volume":"9","author":"Bannister","year":"2015","journal-title":"Curr"},{"key":"R4-20230824","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1016\/j.mayocp.2015.04.003","article-title":"Tapering long-term opioid therapy in chronic noncancer pain: evidence and recommendations for everyday practice","volume":"90","author":"Berna","year":"2015","journal-title":"Mayo Clinic Proc"},{"key":"R5-20230824","doi-asserted-by":"crossref","first-page":"7950","DOI":"10.1523\/JNEUROSCI.23-21-07950.2003","article-title":"Roles of alpha1- and alpha2-adrenoceptors in the nucleus raphe magnus in opioid analgesia and opioid abstinence-induced hyperalgesia","volume":"23","author":"Bie","year":"2003","journal-title":"J Neurosci"},{"key":"R6-20230824","doi-asserted-by":"crossref","first-page":"4074","DOI":"10.1523\/JNEUROSCI.21-11-04074.2001","article-title":"Progressive enhancement of delayed hyperalgesia induced by repeated heroin administration: a sensitization process","volume":"21","author":"Celerier","year":"2001","journal-title":"J Neurosci"},{"key":"R7-20230824","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.jpain.2012.01.001","article-title":"Hyperalgesia in heroin dependent patients and the effects of opioid substitution therapy","volume":"13","author":"Compton","year":"2012","journal-title":"J Pain"},{"key":"R8-20230824","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.drugalcdep.2010.01.006","article-title":"Gabapentin improves cold-pressor pain responses in methadone-maintained patients","volume":"109","author":"Compton","year":"2010","journal-title":"Drug Alcohol Depend"},{"key":"R9-20230824","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1111\/pme.12520","article-title":"Conversion from high-dose full-opioid agonists to sublingual buprenorphine reduces pain scores and improves quality of life for chronic pain patients","volume":"15","author":"Daitch","year":"2014","journal-title":"Pain Med"},{"key":"R10-20230824","first-page":"59","article-title":"Impact of chronic pain on treatment prognosis for patients with opioid use disorder: a systematic review and meta-analysis","volume":"9","author":"Dennis","year":"2015","journal-title":"Subst Abuse"},{"key":"R11-20230824","first-page":"2239","article-title":"Evaluation of clinical and inflammatory profile in opioid addiction patients with comorbid pain: results from a multicenter investigation","volume":"10","author":"Dennis","year":"2014","journal-title":"Neuropsychiatr Dis Treat"},{"key":"R12-20230824","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1016\/S0022-3565(24)37250-7","article-title":"Repetitive opioid abstinence causes progressive hyperalgesia sensitive to N-methyl-D-aspartate receptor blockade in the rat","volume":"284","author":"Dunbar","year":"1998","journal-title":"J Pharmacol Exp Ther"},{"key":"R13-20230824","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/nri3621","article-title":"Pathological pain and the neuroimmune interface","volume":"14","author":"Grace","year":"2014","journal-title":"Nat Rev Immunol"},{"key":"R14-20230824","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1097\/j.pain.0000000000000170","article-title":"Opioid-induced hyperalgesia in community-dwelling adults with chronic pain","volume":"156","author":"Hooten","year":"2015","journal-title":"PAIN"},{"key":"R15-20230824","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1111\/j.1526-4637.2010.00962.x","article-title":"Associations between heat pain perception and opioid dose among patients with chronic pain undergoing opioid tapering","volume":"11","author":"Hooten","year":"2010","journal-title":"Pain Med"},{"key":"R16-20230824","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1100\/tsw.2007.230","article-title":"Opioid-induced glial activation: mechanisms of activation and implications for opioid analgesia, dependence, and reward","volume":"7","author":"Hutchinson","year":"2007","journal-title":"ScientificWorldJournal"},{"key":"R17-20230824","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1056\/NEJMoa1505409","article-title":"Extended-release naltrexone to prevent opioid relapse in criminal justice offenders","volume":"374","author":"Lee","year":"2016","journal-title":"N Engl J Med"},{"key":"R18-20230824","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1177\/0091270011401620","article-title":"Pharmacokinetics of intranasal crushed OxyContin and intravenous oxycodone in nondependent prescription opioid abusers","volume":"52","author":"Lofwall","year":"2012","journal-title":"J Clin Pharmacol"},{"key":"R19-20230824","doi-asserted-by":"crossref","first-page":"ES9","DOI":"10.36076\/ppj.2012\/15\/ES9","article-title":"Opioid epidemic in the United States","volume":"15","author":"Manchikanti","year":"2012","journal-title":"Pain Physician"},{"key":"R20-20230824","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S0304-3959(02)00422-0","article-title":"Opioid-induced abnormal pain sensitivity: implications in clinical opioid therapy","volume":"100","author":"Mao","year":"2002","journal-title":"PAIN"},{"key":"R21-20230824","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s11916-006-0011-5","article-title":"Opioid-induced abnormal pain sensitivity","volume":"10","author":"Mao","year":"2006","journal-title":"Curr Pain Headache Rep"},{"key":"R22-20230824","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1002\/pds.3945","article-title":"A synthesis of oral morphine equivalents (OME) for opioid utilisation studies","volume":"25","author":"Nielsen","year":"2016","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"R23-20230824","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1186\/s13075-014-0504-2","article-title":"The sympathetic nervous response in inflammation","volume":"16","author":"Pongratz","year":"2014","journal-title":"Arthritis Res Ther"},{"key":"R24-20230824","doi-asserted-by":"crossref","first-page":"S80","DOI":"10.1016\/j.jsat.2009.12.007","article-title":"Pain and continued opioid use in individuals receiving buprenorphine-naloxone for opioid detoxification: secondary analyses from the Clinical Trials Network","volume":"38","author":"Potter","year":"2010","journal-title":"J Subst Abuse Treat"},{"key":"R25-20230824","doi-asserted-by":"crossref","first-page":"605","DOI":"10.15288\/jsad.2013.74.605","article-title":"Buprenorphine\/naloxone and methadone maintenance treatment outcomes for opioid analgesic, heroin, and combined users: findings from starting treatment with agonist replacement therapies (START)","volume":"74","author":"Potter","year":"2013","journal-title":"J Stud Alcohol Drugs"},{"key":"R26-20230824","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.drugalcdep.2008.01.012","article-title":"Abnormal heat and pain perception in remitted heroin dependence months after detoxification from methadone-maintenance","volume":"95","author":"Prosser","year":"2008","journal-title":"Drug Alcohol Depend"},{"key":"R27-20230824","doi-asserted-by":"crossref","first-page":"2865","DOI":"10.1097\/j.pain.0000000000000710","article-title":"Withdrawal-associated injury site pain (WISP): a descriptive case series of an opioid cessation phenomenon","volume":"157","author":"Rieb","year":"2016","journal-title":"PAIN"},{"key":"R28-20230824","doi-asserted-by":"crossref","first-page":"e570","DOI":"10.1097\/PR9.0000000000000570","article-title":"The dark side of opioids in pain management: basic science explains clinical observation","volume":"1","author":"Rivat","year":"2016","journal-title":"Pain Rep"},{"key":"R29-20230824","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/B978-0-12-398314-5.00001-5","article-title":"Inflammation in anxiety","volume":"88","author":"Salim","year":"2012","journal-title":"Adv Protein Chem Struct Biol"},{"key":"R30-20230824","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1111\/j.1399-6576.1997.tb04684.x","article-title":"Pharmacokinetic comparison of intravenous and intranasal administration of oxycodone","volume":"41","author":"Takala","year":"1997","journal-title":"Acta Anaesthesiologica Scand"},{"key":"R31-20230824","doi-asserted-by":"crossref","first-page":"343","DOI":"10.5055\/11","article-title":"Is opioid-induced hyperalgesia reversible? A study on active and former opioid addicts and drug naive controls","volume":"8","author":"Treister","year":"2012","journal-title":"J Opioid Manag"},{"key":"R33-20230824","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1056\/NEJMra1507771","article-title":"Opioid Abuse in chronic pain\u2013misconceptions and mitigation strategies","volume":"374","author":"Volkow","year":"2016","journal-title":"N Engl J Med"},{"key":"R34-20230824","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1111\/j.1526-4637.2011.01276.x","article-title":"Longitudinal observation of changes in pain sensitivity during opioid tapering in patients with chronic low-back pain","volume":"12","author":"Wang","year":"2011","journal-title":"Pain Med"},{"key":"R35-20230824","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1016\/j.pain.2010.09.030","article-title":"Central sensitization: implications for the diagnosis and treatment of pain","volume":"152","author":"Woolf","year":"2011","journal-title":"PAIN"}],"container-title":["PAIN Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/01938936-201806000-00006","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T16:50:17Z","timestamp":1786035017000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/01938936-201806000-00006"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5]]},"references-count":34,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.1097\/pr9.0000000000000648","relation":{},"ISSN":["2471-2531"],"issn-type":[{"value":"2471-2531","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,5]]}}}